otonomy  targeted medicines for the ear targeted medicines for the ear home careers contact latest news july  otonomy to report second quarter  financial results and provide corporate update »july  otonomy announces fda acceptance of otiprio® supplemental new drug application filing for acute otitis externa » otividex™a sustainedexposure formulation of the steroid dexamethasone that is in two phase  clinical trials for patients with ménières disease  averts in the us and averts in europe learn more » otoa sustainedexposure formulation of the nmda receptor antagonist gacyclidine for the treatment of tinnitus that will be evaluated in a phase  clinical trial that is expected to start in the second half of  learn more » otoxxotonomy has acquired the rights to multiple product candidates for our fourth development program which will target agerelated hearing loss also known as presbycusis learn more » careers  otonomy targeted medicines for the ear home careers contact careers contact careers our employment philosophy because the quality of otonomy’s employees is the key to our success we carefully select each new employee we are committed to developing products that will benefit people’s lives and build value for our shareholders as a team we value honesty and integrity knowledge initiative and leadership and a commitment to quality and improvement in everything we do we want our decisions and actions to demonstrate these values we treat one another with respect and take pride in the significant contributions that come from teamwork and the diversity of our organization  we strive for excellence and sound responsible decision making we know that otonomy’s success depends on the performance of each member of our team when filling open positions we will always strive to select the most qualified candidate regardless of race color religion sex national origin ancestry age medical condition sexual orientation marital status pregnancy physical or mental disability veteran or other protected status we are proud to be an equal opportunity employer with commitment to affirmative action for minorities women individuals with disabilities and veterans notice to search firmsthird party recruitment agencies recruiters because the human resources team manages the recruitment process for otonomy to protect the interest of all parties involved otonomy will only accept resumes from a recruiter if an executed search agreement is in place at the start of the recruitment effort unsolicited resumes sent to otonomy from recruiters do not constitute any type of relationship between the recruiter and otonomy and do not obligate otonomy to pay fees should we hire from those resumes recruiters are requested not to contact or present candidates directly to our hiring managers or employees current openingspreclinical developmentassociate scientist in vivo the associate scientist in vivo will be responsible for conducting and analyzing in vivo experiments and reporting findings submitting recommendation and design of new experiments and approaches essential functions conducting and analyzing in vivo and ex vivo experiments related to ear disorders and reporting findings submitting recommendations and study design for new experiments and approaches drafting data reports that support scientific findings and manuscripts for potential publication presenting data to supervisor and others at internal and external meetings participating in the development of data utilized in the completion of research grants andor patent applications maintaining a functional knowledge of the theories and techniques of an experienced research scientist in the area of otological preclinical developmentpharmacology and share knowledge with peers and others may perform other related duties as required andor assigned and may train and mentor junior staff all qualified applicants will have the following phd degree or ms degree with additional experience  years of applicable experience in the auditory field willingness and ability to work in a fastpaced environment significant handson experience with ex vivo cochlear assays andor in vivo otology studies tissue culture confocal laser microscopy histology and molecular biology techniques ability to manage and execute on multiple and competing priorities is expected strong communication skills and the ability to work as a team member are essential background in otology preferred equal opportunity employerfemalesminoritiesveteransdisability apply for associate scientist in vivo using the link below httpsworkforcenowadpcomjobsapplypostinghtmlclientotonomyjobidlangenussourcecc   preclinicaldevelopmentmedical affairsmedical science liaison create a strategic advantage for otonomy by being part of a bestinclass medical affairs field medical team that has capabilities to engage all types of kols across the complex landscape of payeracademic and community kols develop strong advocacy with these kols through credible scientific dialogue which contains data from rcts amcp dossiers qol tools database claims analysis population health research as well as health economic and outcomes research significant previous experience with scientific and medical aspects of market access andor medical patient access role is required and the necessary payer skills to be part of an innovative msl team with broad capabilities ones that enable them to communicate many different types of data beyond rcts including amcp dossiers of value to the payer kolformulary decision maker this type of small nimble biopharma medical team will be able to flex across the spectrum of payeracademiccommunity kols and will have documented experience of success in previous patient access roles msl will be a field based team member that is able to flex across the spectrum of kols given the evolution of their interests scientific needs and the complex landscape which includes payersacademiccommunity kols and pt decision makers location this role is remote the preferred location for the role is on the east coast midwest and west coast essential functions capability of developing medical advocacy with payeracademiccommunity kols and enthusiasm for the scientific basis of otonomy’s product portfolio develop strong advocacy with the spectrum of kols through credible scientific dialogue which contains data from rcts amcp dossier quality of life tools qol database claims analysis budget impact models as well as health economics  outcomes research working with the reimbursement and market access teams help achieve patient access objectives formulary approval and payer coverage for otonomy’s portfolio though the use of scientific and medical information stay abreast of medical reimbursement best practices and build relationships with key payer decision makers highly skilled in the medical and scientific aspects of patient access the msl will partner with reimbursement and market access teams in a compliant manner and consistent with our sops to create access for patients to otonomy’s portfolio execute on kol engagement metrics for all types of kols and quality of carehealth outcomes organizations in a compliant manner and consistent with our sops assist with the appropriate use of medical advisory boards and medical advocacy activities responds to medical inquiries from the spectrum of kols by providing timely accurate scientific data in a compliant manner supports the commercial team in a compliant manner and consistent with our sops with medical and scientific expertise as requested  provides sales force with training at national and regional levels as requested assists in the selection and training of appropriate healthcare professionals participating in the commercial speaker’s bureau effectively and compliantly responds to requests for medical information from the spectrum of stakeholders covering important scientific topics from clinical trials preclinical data drug safety and medical information etc represents otonomy at specific continuing educational eventsprograms medical meetings and conventions executes congress strategy and develops key insights for internal education and supporting the development of our strategic plan supports clinical development with kol insights and other requests clinical development may have of the msl team may provide medical and scientific insight to otonomy’s business development group and other parties on new disease opportunities that align with otonomy’s current technology and corporate strategy as well as new technologies may perform other related duties as required andor assigned bachelor’s degree in a scientific or related field with advanced degree required ie pharm d md phd minimum  years of relevant experience in the biopharmaceutical industry including significant previous experience as an msl in the biopharmaceutical industry significant previous experience and history in a full time role involving medical aspects of market access andor medical patient access role within the biopharma industry prior experience in a medical patient access role with a biotechnology or pharmaceutical company ie full time responsibility for payer engagement managed care national accounts heor payer field team etc proven experience executing strategy for formulary success payer coverage influencing quality of care organizations and implementing operational plans significant capabilities in capturing kol insights across the spectrum of payeracademiccommunity kols and demonstrated experience applying those insights in the development of payer dossiers and heor previous experience creating advocacy with payeracademiccommunity kols through credible scientific dialogue that includes rcts payer dossiers heor qol tools bims and surveys previous experience demonstrating success with advocacy and accountability for medical metrics excellent communication skills public speaking  exchanges written communications as well as the ability to work collaboratively with several teams in the field such as sales market access and national accounts must be fully cognizant of all relevant complex scientific data and complex regulatory requirements for fieldbased personnel this includes understanding and remaining vigilant with compliance and current sops must be committed to continuing education to maintain knowledge base please use the link below to view the full job  description and apply httpsworkforcenowadpcomjobsapplypostinghtmlclientotonomyjobidlangenussourcecc medicalaffairsclinical developmentdirector drug safety the director of drug safety will be responsible for directing the safety surveillance of company investigational and postmarketed drug products essential functions oversee drug safety processes for clinical programs and postmarketed products identify and respond to drug safety issues and implement actions to improve drug safety provide medical and scientific review and evaluation of safety information and adverse event reports for both marketed and investigational medicinal products work in conjunction with clinical trial medical monitors to coordinate medical monitoring of ongoing clinical trials contribute to and review drug safety section of clinical trial protocols case report forms adverse eventsae reporting forms and clinical study reports for projects contribute to and review drug safety sections of regulatory submissions and safety updates develop andor review studyspecific safety monitoring plans documents and tools to ensure the consistent and timely reporting of saes oversee thirdparty safety reporting vendor generate and review individual adverse event reports adverse event tabulations and data summaries and prepareswrites periodic safety reports review coding of meddra who drug for aes and com meds and medical history lead the setup and running of the dsmb as required review postmarket pharmacovigilance plan reviewapprove postmarket spontaneous ae narratives and reports and literature reports provided by safety vendors completenessaccuracy and classification for regulatory reporting review clinical safety data during data cleaning responsible for sops for safetypharmacovigilance travel is required  to investigator meetings and company meetings which may include international travel all qualified applicants will have the following bsba rn phd or pharmacy degree or related field or the equivalent education and experience must have a minimum of  years of experience in the pharmaceutical industry or cro with at least  years in drug safety operations pharmacovigilance and risk assessment an indepth knowledge and thorough understanding of fda eu and global regulations ich guidelines and gcps that govern drug safety and pharmacovigilance are required high level of understanding of global regulatory requirements for drug safety reporting with recent experience in clinical drug safety assessment and reporting solid understanding of global gcp requirements must be a demonstrated selfstarter and team player with strong interpersonal skills excellent communication skills and ability to work effectively with vendors and personnel at clinical sites strong written communications                                                                                                                                         equal opportunity employerfemalesminoritiesveteransdisability apply for director drug safety using the link below httpsworkforcenowadpcomjobsapplypostinghtmlclientotonomyjobidlangenussourcecc clinicaldevelopment to apply please send your resume with salary requirements to careersotonomycom or mail to  executive drive san diego ca  attention human resources otonomy is an equal opportunity employer executive team  otonomy targeted medicines for the ear home careers contact about our story management team board of directors  david a weber phdchief executive officer president and board member david a weber phd has served as our president and chief executive officer and on our board of directors since november  prior to joining us dr weber served from february  to april  as the chief executive officer of macusight inc a developer of a sustained delivery formulation of sirolimus for the treatment of severe ophthalmic diseases prior to macusight dr weber served as acting chief executive officer and executive vice president of oculex pharmaceuticals inc a specialty pharmaceutical company focused on the development and commercialization of intraocular pharmaceuticals and drug delivery systems until its acquisition by allergan in  dr weber has also held management positions with oralb laboratories a developer and manufacturer of oral hygiene products and with procter  gamble co a consumer products company dr weber received his phd in medical microbiology from creighton university and his master’s and bachelor’s degrees in biological sciences from wichita state university kathie m bishop phdchief scientific officer kathie m bishop phd was appointed as our chief scientific officer in november  and joined the company beginning in january  dr bishop is a neuroscientist with more than fifteen years of pharmaceutical development experience prior to otonomy she served as chief scientific officer of tioga pharmaceuticals from may  to november  from september  to april  she served in various product development management roles at ionis pharmaceuticals including vice president clinical development at ionis she led translational research and development of multiple preclinical and clinical programs in the neurology franchise including spinraza™ nusinersen a treatment for patients with spinal muscular atrophy that is awaiting regulatory approval from august  to september  dr bishop served in research and development leadership roles at ceregene a company focused on the development of gene therapy products for the treatment of neurodegenerative disorders and retinal diseases from september  to july  she worked as a postdoctoral fellow in the molecular neurobiology lab at the salk institute for biological studies dr bishop obtained a phd in neuroscience from the university of alberta and bachelor’s degrees in cell biology and genetics from the university of british columbia and psychology from simon fraser university paul e cayerchief financial  business officer paul e cayer has served as our chief business officer since october  and chief financial officer since october  mr cayer brings more than  years of experience in the pharmaceutical medical device and healthcare technology field prior to joining our company mr cayer served from  to  as senior vice president corporate development for verus pharmaceuticals inc a specialty pharmaceutical company focused on the treatment of allergic and respiratory disorders in children from  to  mr cayer served as the chief financial officer and senior vice president business development of targeted molecules corporation a biopharmaceutical company mr cayer has also held various management positions with gensia pharmaceuticals inc a biopharmaceutical company acuson a provider of medical ultrasound systems castle  cooke a consumer products company and served as consultant with boozallen  hamilton a management and technology consulting firm mr cayer received his mba and bachelor’s degree in biomechanical engineering from harvard university dean hakanson mdchief medical officer dean hakanson md has served as our chief medical officer since april  from may  to march  dr hakanson served as vice president and head of health economics and outcomes research for us medical and regulatory affairs and from july  to may  as vice president and medical head of the western us operating unit for novartis ag a pharmaceutical company from january  to july  dr hakanson served as vice president of healthcare access for bristolmyers squibb company a manufacturer of prescription pharmaceuticals from june  to january  dr hakanson served as head of valuebased health carepayer field team for genentech inc a biotechnology corporation which is now a division of f hoffmanla roche ag from  to  he held various positions at glaxosmithkline plc a pharmaceutical and consumer healthcare company which included vice president medical affairs commercial operations and vice president of managed markets national accounts earlier in his career he practiced clinical medicine in critical care at john c lincoln ids and tenet healthcare corporation he is also a fellow with the american academy of otolaryngology – head and neck surgery and a diplomat of the american board of anesthesiology american medical association and the american association for physician leadership currently he has an active license to practice medicine in california and arizona dr hakanson received his bachelor’s degree in cellular physiology and physics from the university of denver a medical degree from the university of colorado school of medicine anesthesiology residency training at the university of michigan and training in critical care at the university of california davis medical center eric loumeaugeneral counsel and chief compliance officer eric loumeau has served as our general counsel and chief compliance officer since may  and secretary since july  mr loumeau brings over  years of experience as inhouse legal counsel and compliance officer for several biopharmaceutical companies and as outside corporate counsel supporting healthcare and technology based client companies prior to joining our company mr loumeau was the vice president of legal affairs at the medicines company from december  to may  a role he held following the companys acquisition of rempex pharmaceuticals from june  to december  mr loumeau served as vice president chief financial officer and chief compliance officer of rempex pharmaceuticals from january  to january  he was partner at bass berry  sims plc and from may  to january  he was partner at mintz levin cohn ferris glovsky and popeo pc from october  to may  mr loumeau served as general counsel and chief compliance officer for holliseden pharmaceuticals a publicly traded biotechnology company prior to this role he was partner and associate at cooley llp from april  to october  and an associate at skadden arps slate meagher  flom llp from september  to april  mr loumeau obtained a juris doctorate from boalt hall school of law at the university of california berkeley including spending his final year at harvard law school through the harvardboalt exchange program he obtained a bachelors degree in finance from brigham young university  robert michael savel iichief technical officer robert michael savel ii has served as our chief technical officer since january  from september  to december  mr savel served as general manager and senior vice president of operations for optimer pharmaceuticals inc a biopharmaceuticals company from september  to june  mr savel served as senior vice president and chief technical officer for inspire pharmaceuticals inc an ophthalmic pharmaceutical company from april  to september  mr savel served as president of savel enterprises llc a management consulting firm from april  to april  mr savel served as the senior vice president of technical operations for pdl biopharma an antibody manufacturer earlier in his career he held leadership operating positions with johnson  johnson a medical devices pharmaceutical and consumer packaged goods manufacturer which included the position of vice president quality and compliance mr savel received his bachelor’s degree in mechanical engineering from virginia polytechnic institute and state university in blacksburg virginia pipeline  otonomy targeted medicines for the ear home careers contact pipeline product candidates otiprio® otividex™ oto otoxx clinical trials expanded access policy pipeline otonomy’s mission is to develop and commercialize therapeutics to address the significant unmet medical needs in the otology market product candidateinvestigational indication preclinical phase  phase  phase  registration otiprio® ciprofloxacin otic suspension acute otitis externa “swimmer’s ear”  otiprio ciprofloxacin otic suspension acute otitis media with tubes aomt  otividex™dexamethasone ménière’s disease  otividex™dexamethasone cisplatininduced hearing loss in pediatrics  otogacyclidine tinnitus  otoxx sensorineural hearing loss  for additional information about otonomy’s delivery technology click here the safety and efficacy of otiprio for these uses has not been established and is under clinical investigation contact  otonomy targeted medicines for the ear home careers contact careers contact contact view google map » otonomy inc  executive drive san diego ca  local phone   tollfree otonomy  fax   infootonomycom adverse event and product complaint reporting to report a productrelated adverse event or a product complaint please contact otonomy by phone at  or by email at medinfootonomycom medical information for health care providers who have a productrelated medical inquiry please contact otonomy medical information by phone at  or by email at medinfootonomycom clinical trials for patients and health care providers who are interested in learning more about our ongoing clinical trials please contact the otonomy clinical trial information group by phone at otoinfo  or by email at clinicaltrialsotonomycom our story  otonomy targeted medicines for the ear home careers contact about our story management team board of directors our story in  jay lichter phd a partner at avalon ventures and biotechnology industry veteran experienced his first severe attack of vertigo while driving he became severely disoriented and had to pull to the side of the road after multiple doctor visits he was diagnosed with ménière’s disease and quickly experienced the limitations of available treatments with his physician jeffrey harris md phd chief of the division of otolaryngologyhead and neck surgery at the university of california san diego and several other experts in the field of otology dr lichter founded otonomy to bring new treatment options to patients with otic ear disorders our mission today remains the same – to develop and commercialize novel and bestinclass therapeutics to address the significant unmet medical needs in the emerging otology market to overcome many of the limitations of delivering drugs to the ear we have developed a proprietary technology that is designed to deliver drug that is retained in the ear for an extended period of time following a single local administration which we refer to as “sustainedexposure” utilizing this technology we have advanced multiple product candidates into development and launched our first product otiprio® ciprofloxacin otic suspension otiprio is a singledose physicianadministered antibacterial and the first product approved by the fda for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement  press releases  otonomy targeted medicine for the ear homecareerscontactoverviewpress releasesevents and presentationscorporate governancefinancial informationstock informationanalyst coverageinvestor faqscontact usprint page email page rss feeds xshare onfacebooktwitterlinkedingoogleredditdigggoogledeliciousstumbleuponwhats thisshare this page through your favorite social channel or email this page to a colleagueshare page email alerts financial tear sheet  press releases      previous releasesjuly  otonomy to report second quarter  financial results and provide corporate updatejuly  otonomy announces fda acceptance of otiprio® supplemental new drug application filing for acute otitis externajune  otonomy announces successful endofphase  review by fda for otiprio® in acute otitis media with tympanostomy tubesjune  otonomy to host key opinion leader meeting for investors on ménières diseasemay  otonomy announces otiprio® data presentation and symposium at the american society of pediatric otolaryngology annual meetingmay  otonomy to present at the bank of america merrill lynch health care conferencemay  otonomy reports first quarter  financial results and provides corporate updateapril  otonomy to report first quarter  financial results and provide corporate updatemarch  otonomy reports fourth quarter and full year  financial results and provides corporate updatefebruary  otonomy to present at cowen and company health care conferencefebruary  otonomy to report fourth quarter and full year  financial results and provide corporate updatejanuary  otonomy initiates patient enrollment in phase  clinical trial of oto as protectant against cisplatininduced hearing lossjanuary  otonomy provides corporate and product pipeline updatejanuary  otonomy announces positive topline results from phase  clinical trial of otiprio® in patients with acute otitis externajanuary  otonomy to present at the jp morgan healthcare conference pipeline  otonomy targeted medicines for the ear home careers contact pipeline product candidates otiprio® otividex™ oto otoxx clinical trials expanded access policy pipeline otonomy’s mission is to develop and commercialize therapeutics to address the significant unmet medical needs in the otology market product candidateinvestigational indication preclinical phase  phase  phase  registration otiprio® ciprofloxacin otic suspension acute otitis externa “swimmer’s ear”  otiprio ciprofloxacin otic suspension acute otitis media with tubes aomt  otividex™dexamethasone ménière’s disease  otividex™dexamethasone cisplatininduced hearing loss in pediatrics  otogacyclidine tinnitus  otoxx sensorineural hearing loss  for additional information about otonomy’s delivery technology click here the safety and efficacy of otiprio for these uses has not been established and is under clinical investigation otonomy inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports otonomy inc  product pipeline review   otonomy inc  product pipeline review   wgr  november  global  pages global markets direct description table of content sample report enquiry before buy related reports otonomy inc  product pipeline review  summaryglobal markets direct’s ‘otonomy inc  product pipeline review  ’ provides an overview of the otonomy inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of otonomy inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of otonomy inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of otonomy inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the otonomy inc’s pipeline productsreasons to buy evaluate otonomy inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of otonomy inc in its therapy areas of focus identify new drug targets and therapeutic classes in the otonomy inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of otonomy inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of otonomy inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of otonomy inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures otonomy inc snapshot otonomy inc overview key information key facts otonomy inc  research and development overview key therapeutic areas otonomy inc  pipeline review pipeline products by stage of development pipeline products  monotherapy otonomy inc  pipeline products glance otonomy inc  late stage pipeline products phase iii productscombination treatment modalities otonomy inc  clinical stage pipeline products phase ii productscombination treatment modalities otonomy inc  early stage pipeline products preclinical productscombination treatment modalities otonomy inc  drug profiles ciprofloxacin sr product description mechanism of action rd progress dexamethasone acetate sr product description mechanism of action rd progress gacyclidine product description mechanism of action rd progress otonomy inc  pipeline analysis otonomy inc  pipeline products by target otonomy inc  pipeline products by route of administration otonomy inc  pipeline products by molecule type otonomy inc  pipeline products by mechanism of action otonomy inc  recent pipeline updates otonomy inc  locations and subsidiaries head office appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesotonomy inc key information otonomy inc key facts otonomy inc  pipeline by indication  otonomy inc  pipeline by stage of development  otonomy inc  monotherapy products in pipeline  otonomy inc  phase iii  otonomy inc  phase ii  otonomy inc  preclinical  otonomy inc  pipeline by target  otonomy inc  pipeline by route of administration  otonomy inc  pipeline by molecule type  otonomy inc  pipeline products by mechanism of action  otonomy inc  recent pipeline updates  list of figuresotonomy inc  pipeline by top  indication  otonomy inc  pipeline by stage of development  otonomy inc  monotherapy products in pipeline  otonomy inc  pipeline by top  target  otonomy inc  pipeline by top  route of administration  otonomy inc  pipeline by top  molecule type  otonomy inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send otic key statistics  otonomy inc financial ratios  marketwatch bulletin intel shares climb on strong earnings upbeat outlook » amazon shares fall over  after big earnings miss » investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close otonomy inc nasdaq otic go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus otonomy inc after hours  quotes are delayed by  min jul    pm otic quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite todays close     change   day low day high    week low  week high   company description otonomy inc engages in the research development and manufacture of biopharmaceutical products the firms portfolio includes therapeutics for diseases and disorders of the ear such as otitis media acute otitis externa balance disorders ménières disease tinnitus cisplatininduced hearing lo otonomy inc engages in the research development and manufacture of biopharmaceutical products the firms portfolio includes therapeutics for diseases and disorders of the ear such as otitis media acute otitis externa balance disorders ménières disease tinnitus cisplatininduced hearing loss and sensorineural hearing loss it operates under the otiprio brand the company was founded by jay b lichter jeffrey harris rick friedman and allen f ryan in april  and is headquartered in san diego ca valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure officers and executives name age officer since title dr jay b lichter   chairman dr david a weber   president chief executive officer  director mr paul e cayer   cfo chief business  principal accounting officer dr katherine m bishop   chief scientific officer dr dean hakanson   chief medical officer insider actions – purchase – sale  – number of transactions  sponsored topics see a problem let us know legal help otonomy inc nasdaqotic quotes  news  google financecookies help us deliver our services by using our services you agree to our use of cookieslearn moregot itmy accountsearchmapsyoutubeplaynewsgmaildrivecalendargoogletranslatephotosmoreshoppingwalletfinancedocsbooksbloggercontactshangoutskeepeven more from googlesign inhidden fieldssearch financeadobe flash player is required for interactive charts allowfinanceotonomy incnasdaqoticadd to portfoliocompanysummarynewsrelated companieshistorical pricesfinancialsmarketsnewsportfoliosstock screenergoogle domestic trendsrecent quotes  daysyou have no recent quoteschg   otonomy inc  public nasdaqotic   watch this stock      after hours    jul  pm edt   nasdaq realtime data  disclaimer currency in usd range     week    open  vol  avg  mkt cap m pe      divyield      eps  shares m beta      inst own  news relevance date all news for otonomy inc » subscribe advertisement events add otic to my calendars aug   q  otonomy inc earnings release estimated  pm edt  jun   otonomy inc  kol breakfast event  may   otonomy inc at bank of america merrill lynch healthcare conference may   q  otonomy inc earnings call may   q  otonomy inc earnings release more events from dailyfinance »     key stats and ratios q mar   net profit margin   operating margin   ebitd margin   return on average assets   return on average equity   employees   cdp score   screen stocks with similar metrics » address  executive drsan diego ca united states  map phone fax website links httpwwwotonomycom external links analyst estimates  marketwatch sec filings  edgar online major holders  msn money research reports  reuters settings  technicals  link to this view volume delayed by  minsprices are not from all markets sources include six advertisement related companies show most recent quarter most recent annual add or remove columns save changes cancel sector healthcare  industry bio therapeutic drugs more from factset » description otonomy inc is a biopharmaceutical company the company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear the companys product candidates include otiprio oto and oto otiprio is a singledose physicianadministered antibacterial which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement ttp surgery and is available for commercial purchase oto is a sustainedexposure formulation of the steroid dexamethasone in development for the treatment of menieres disease and other inner ear conditions oto is a sustainedexposure formulation of the nmethyldaspartate nmda receptor antagonist gacyclidine in development for the treatment of tinnitus it also has various other product candidates which target sensorinerual hearing loss including agerelated hearing loss also known as presbycusis more from reuters » officers and directors jay lichter phd independent chairman of the board age  bio  compensation   reuters david a weber phd president chief executive officer director age  bio  compensation   reuters paul e cayer chief financial and business officer age  bio  compensation   reuters robert michael savel ii chief technical officer age  bio  compensation   reuters kathie m bishop phd chief scientific officer age  bio  compensation   reuters eric j loumeau chief compliance officer general counsel secretary age  bio  compensation   reuters dean hakanson md chief medical officer age  bio  compensation   reuters vickie l capps independent director age  bio  compensation   reuters iain r mcgill independent director age  bio  compensation   reuters george j morrow independent director age  bio  compensation   reuters full list on reuters » google finance beta available in hong kong  canada  us  china  ukinformation is provided as is and solely for informational purposes not for trading purposes or advice and may be delayedto see all exchange delays please see disclaimer google  google home  blog  help  report a problem  privacy policy  terms of service otonomy  targeted medicines for the ear targeted medicines for the ear home careers contact latest news july  otonomy to report second quarter  financial results and provide corporate update »july  otonomy announces fda acceptance of otiprio® supplemental new drug application filing for acute otitis externa » otividex™a sustainedexposure formulation of the steroid dexamethasone that is in two phase  clinical trials for patients with ménières disease  averts in the us and averts in europe learn more » otoa sustainedexposure formulation of the nmda receptor antagonist gacyclidine for the treatment of tinnitus that will be evaluated in a phase  clinical trial that is expected to start in the second half of  learn more » otoxxotonomy has acquired the rights to multiple product candidates for our fourth development program which will target agerelated hearing loss also known as presbycusis learn more » bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one